Elimika Pfuma Fletcher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elimika Pfuma Fletcher has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Gilbert J. Burckart
Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, USA
6 shared publications - Rajanikanth Madabushi
United States Food and Drug Administration 1 Silver Spring
6 shared publications - Anuradha Ramamoorthy
Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research Food and Drug Administration Silver Spring Maryland USA
3 shared publications Daphne Guinn
Office of Clinical Pharmacology Office of Translational Sciences Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring MD USA
3 shared publications- Stephan Schmidt
Center for Pharmacometrics and Systems Pharmacology Department of Pharmaceutics College of Pharmacy University of Florida Orlando Florida USA
3 shared publications - Susan M. Abdel-Rahman
Office of Clinical Pharmacology Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring MD USA
3 shared publications
Latest Publications
- 6 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
Impact of Dosage Modifications on Efficacy: Insights from Select Tyrosine Kinase Inhibitors Approved for Treatment of Non-Small Cell Lung Cancer with EGFR Mutations
Purpose: Dosage modifications, including dose interruptions and reductions, are commonly implemented to manage adverse reactions observed with oncology drugs. However, their impact on efficacy is not well understood. Here, we explored the impact of dosage modifications on progression free survival (PFS) and overall survival (OS) for four US FDA-approved tyrosine kinase inhibitors for the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. Methods: We collected patient-level data from clinical trials supporting the original FDA approvals of afatinib, dacomitinib, mobocertinib, and osimertinib. We identified the daily dose received (DDR; a measure of the dosage received by a patient each day), dose interruptions and reductions over the treatment period. In this exploratory analysis, we used a time-dependent Cox proportional hazards model to assess the impact of DDR on PFS and landmark time-fixed Cox models at 30, 60, and 90 days from treatment initiation to assess the impact of early dose interruptions and reductions on PFS and OS.Results: While the impact of dose interruptions and reductions on the risk of death varied among the studied drugs, dose interruptions, such as interruptions for four or more consecutive days, were more often associated with a higher risk of progression or death than dose reductions. Conclusion: For the evaluated drugs as monotherapy in NSCLC with EGFR mutations, our analysis suggests that dose reductions might have a lower impact on efficacy than missing or interrupting treatment. Further studies are needed to evaluate other EGFR treatments, drug classes, and cancer types.
- 6 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
Impact of Dosage Modifications on Efficacy: Insights from Select Tyrosine Kinase Inhibitors Approved for Treatment of Non-Small Cell Lung Cancer with EGFR Mutations
Purpose: Dosage modifications, including dose interruptions and reductions, are commonly implemented to manage adverse reactions observed with oncology drugs. However, their impact on efficacy is not well understood. Here, we explored the impact of dosage modifications on progression free survival (PFS) and overall survival (OS) for four US FDA-approved tyrosine kinase inhibitors for the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. Methods: We collected patient-level data from clinical trials supporting the original FDA approvals of afatinib, dacomitinib, mobocertinib, and osimertinib. We identified the daily dose received (DDR; a measure of the dosage received by a patient each day), dose interruptions and reductions over the treatment period. In this exploratory analysis, we used a time-dependent Cox proportional hazards model to assess the impact of DDR on PFS and landmark time-fixed Cox models at 30, 60, and 90 days from treatment initiation to assess the impact of early dose interruptions and reductions on PFS and OS.Results: While the impact of dose interruptions and reductions on the risk of death varied among the studied drugs, dose interruptions, such as interruptions for four or more consecutive days, were more often associated with a higher risk of progression or death than dose reductions. Conclusion: For the evaluated drugs as monotherapy in NSCLC with EGFR mutations, our analysis suggests that dose reductions might have a lower impact on efficacy than missing or interrupting treatment. Further studies are needed to evaluate other EGFR treatments, drug classes, and cancer types.
- 3 September 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 120 (5) , 1227-1239
Secondary Pharmacology Targets for Pediatric Developmental Safety Assessment of New Drugs: Clinical Pharmacology Considerations
Drug safety in pediatric patients has always been a concern. Major tragedies with drugs in pediatric patients created an environment of caution, but the experience with pediatric legislation and drug development over the past 20 years has eased the cautionary approach to pediatric drug safety. The advent of new methods of safety testing, driven by the movement away from animal use in research, provides new opportunities to screen for and prevent adverse developmental effects of drugs on pediatric patients. One approach that can be explored for use in pediatric developmental safety testing is secondary pharmacology, or screening for off‐target drug effects. Secondary pharmacology, which is an established screening mechanism described in ICH S7A, could provide the opportunity to answer important off‐target questions. Examples of 12 specific secondary pharmacology targets related to adverse effects on pediatric development are provided. Clinical pharmacology plays a critical role in the interpretation of secondary pharmacology through quantitative studies necessary to validate positive findings and through the final assessment of the risk:benefit associated with these findings. In conclusion, secondary pharmacology screening has the potential to reduce animal testing while addressing two critical objectives: screening drugs for off‐target effects and providing information on off‐target effects relevant to pediatric developmental safety.
- 3 September 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 120 (5) , 1227-1239
Secondary Pharmacology Targets for Pediatric Developmental Safety Assessment of New Drugs: Clinical Pharmacology Considerations
Drug safety in pediatric patients has always been a concern. Major tragedies with drugs in pediatric patients created an environment of caution, but the experience with pediatric legislation and drug development over the past 20 years has eased the cautionary approach to pediatric drug safety. The advent of new methods of safety testing, driven by the movement away from animal use in research, provides new opportunities to screen for and prevent adverse developmental effects of drugs on pediatric patients. One approach that can be explored for use in pediatric developmental safety testing is secondary pharmacology, or screening for off‐target drug effects. Secondary pharmacology, which is an established screening mechanism described in ICH S7A, could provide the opportunity to answer important off‐target questions. Examples of 12 specific secondary pharmacology targets related to adverse effects on pediatric development are provided. Clinical pharmacology plays a critical role in the interpretation of secondary pharmacology through quantitative studies necessary to validate positive findings and through the final assessment of the risk:benefit associated with these findings. In conclusion, secondary pharmacology screening has the potential to reduce animal testing while addressing two critical objectives: screening drugs for off‐target effects and providing information on off‐target effects relevant to pediatric developmental safety.
- 28 July 2026
- Published by Springer Nature in The AAPS Journal
- Vol. 28 (5) , 124
Assessment of Sorbitol as a Pharmaceutical Excipient in Oral Liquid Pediatric Formulations Submitted to the U.S. FDA
- 28 July 2026
- Published by Springer Nature in The AAPS Journal
- Vol. 28 (5) , 124
Assessment of Sorbitol as a Pharmaceutical Excipient in Oral Liquid Pediatric Formulations Submitted to the U.S. FDA
- Open Access
- 18 February 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (2) , e70503
Informing Dose for Pediatric Rare Diseases—A Survey of Recent Orphan Drugs Approvals
Collectively, pediatric rare diseases affect millions of children worldwide. Yet, treatment options are limited. Dose selection presents unique challenges in pediatric rare disease drug development. Traditional dose‐finding approaches are impractical for these populations, and conventional pediatric dosing methods like exposure matching face limitations when insufficient adult data exists. Herein, we analyzed dosing strategies and study design characteristics used for new molecular entities (NMEs) for orphan indications approved between 2013 and 2022 that included a pediatric indication at initial approval. Among 63 evaluable products included in this analysis, initial pediatric dose selection was supported by adult data in the same indication (37%), adult healthy volunteer data (33%), nonclinical data only (14%), adult data from different indications (10%), and pediatric data from different indications (5%). The use of modeling and simulation to support initial dose selection was explicitly mentioned for 21% of products. Nearly half (48%) utilized multiple data sources for dose selection. Study design characteristics included multiple dose level evaluation (49%), intra‐patient dose escalation (33%), interim pharmacokinetic evaluation (10%), pharmacokinetic/biomarker‐driven dosing (5%), and age group staggering (5%). Multiple design features were incorporated in 17% of drugs. This analysis reveals diverse approaches to pediatric dose selection in rare diseases and the use of adaptive study design elements suggests recognition of the need for flexible approaches in these challenging populations. Utility of modeling and simulation, ability to leverage all available data sources, and increased implementation of adaptive trial designs could improve dose selection and optimization in pediatric rare disease drug development.
- 18 February 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (2) , e70503
Open AccessInforming Dose for Pediatric Rare Diseases—A Survey of Recent Orphan Drugs Approvals
Collectively, pediatric rare diseases affect millions of children worldwide. Yet, treatment options are limited. Dose selection presents unique challenges in pediatric rare disease drug development. Traditional dose‐finding approaches are impractical for these populations, and conventional pediatric dosing methods like exposure matching face limitations when insufficient adult data exists. Herein, we analyzed dosing strategies and study design characteristics used for new molecular entities (NMEs) for orphan indications approved between 2013 and 2022 that included a pediatric indication at initial approval. Among 63 evaluable products included in this analysis, initial pediatric dose selection was supported by adult data in the same indication (37%), adult healthy volunteer data (33%), nonclinical data only (14%), adult data from different indications (10%), and pediatric data from different indications (5%). The use of modeling and simulation to support initial dose selection was explicitly mentioned for 21% of products. Nearly half (48%) utilized multiple data sources for dose selection. Study design characteristics included multiple dose level evaluation (49%), intra‐patient dose escalation (33%), interim pharmacokinetic evaluation (10%), pharmacokinetic/biomarker‐driven dosing (5%), and age group staggering (5%). Multiple design features were incorporated in 17% of drugs. This analysis reveals diverse approaches to pediatric dose selection in rare diseases and the use of adaptive study design elements suggests recognition of the need for flexible approaches in these challenging populations. Utility of modeling and simulation, ability to leverage all available data sources, and increased implementation of adaptive trial designs could improve dose selection and optimization in pediatric rare disease drug development.
- 10 February 2026
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 66 (2) , e70160
Drug Administration via Enteral Feeding Tubes: A Landscape Analysis of Information in Drug Product Labeling
Oral drug products are sometimes administered via enteral feeding tubes in populations with temporary or long‐term swallowing disorders or difficulties. Health care providers require product‐specific information regarding appropriate administration of drug products through enteral tubes to avoid occlusion of tubes and ensure the safe and effective use of the drug products. In this review, the enteral tube‐related information in drug product labeling is characterized to better understand how such information is conveyed to health care professionals to help inform their clinical decision‐making. The review identified 71 unique drug products with labeling related to administration via enteral feeding tube. Of those, 85% discussed the type of feeding tube and 46% discussed enteral tube size. Only 14% discussed the tubing material and 8% discussed timing of enteral feeds as it relates to dosing. The effect of enteral tube administration on the pharmacokinetics of the drug was only included in 18% of the drug product labeling. The high variability in the type and extent of enteral tube‐related information in the drug product labeling suggests that innovative strategies are needed to help inform optimal use of drug products administered using this method. The few labeling that discuss feeding tube administration raises broader questions of if, and how, these data should be more consistently studied and included in labeling. Collaborative efforts from multiple stakeholders including drug developers and regulators can effectuate improvements in this area.
- 10 February 2026
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 66 (2) , e70160
Drug Administration via Enteral Feeding Tubes: A Landscape Analysis of Information in Drug Product Labeling
Oral drug products are sometimes administered via enteral feeding tubes in populations with temporary or long‐term swallowing disorders or difficulties. Health care providers require product‐specific information regarding appropriate administration of drug products through enteral tubes to avoid occlusion of tubes and ensure the safe and effective use of the drug products. In this review, the enteral tube‐related information in drug product labeling is characterized to better understand how such information is conveyed to health care professionals to help inform their clinical decision‐making. The review identified 71 unique drug products with labeling related to administration via enteral feeding tube. Of those, 85% discussed the type of feeding tube and 46% discussed enteral tube size. Only 14% discussed the tubing material and 8% discussed timing of enteral feeds as it relates to dosing. The effect of enteral tube administration on the pharmacokinetics of the drug was only included in 18% of the drug product labeling. The high variability in the type and extent of enteral tube‐related information in the drug product labeling suggests that innovative strategies are needed to help inform optimal use of drug products administered using this method. The few labeling that discuss feeding tube administration raises broader questions of if, and how, these data should be more consistently studied and included in labeling. Collaborative efforts from multiple stakeholders including drug developers and regulators can effectuate improvements in this area.
- 22 November 2025
- Published by Springer Nature
- p. 95-109
Clinical Pharmacology of Topical Therapy in Pediatrics
- 22 November 2025
- Published by Springer Nature
- p. 95-109
Clinical Pharmacology of Topical Therapy in Pediatrics
- 22 November 2025
- Published by Springer Nature
- p. 83-93
Clinical Pharmacology of Dermatology Products in Pediatric Drug Development
- 22 November 2025
- Published by Springer Nature
- p. 83-93
Clinical Pharmacology of Dermatology Products in Pediatric Drug Development
- Open Access
- 25 September 2025
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 14 (12) , 2118-2127
Evaluation and Mitigation of Time‐Dependent Confounding Effects in Conventional Exposure‐Response Analyses for Oncology Drugs
Conventional exposure–response (E–R) analyses, such as logistic regression and time‐to‐event analysis using summary exposure metrics, are often conducted in oncology using data from the pivotal trial(s) with a single dose level to support dosing decisions. However, these E–R analyses, affected by multiple confounding factors, may mischaracterize true E–R relationships, potentially limiting their utility in dosing decisions. This study investigates potential mischaracterization in such analyses influenced by the following time‐dependent confounding factors: exposure accumulation, dose modification patterns, and event onset time. We used a simulation‐based approach to evaluate two E–R scenarios: ER1, where event time generated with a Weibull distribution is not affected by drug exposure, and ER2, where the response is driven by drug exposure via a joint PK‐tumor size model. Our analyses indicate that when using time‐dependent exposure metrics (e.g., average concentration till event/censoring), exposure accumulation tends to induce an inverse E–R trend, while dose modifications (interruptions/reductions) likely induce a positive E–R trend. Simulations suggest that employing static exposure metrics (e.g., first‐cycle or steady‐state) minimizes these biases. Additionally, adopting an E max model aligned with the underground truth in ER2 in the E–R analyses could reduce bias. When significant dose modifications are present, including relevant data from a dose‐range study and employing modified methods for time‐dependent exposure derivation may help mitigate bias. Overall, using multiple exposure metrics (including static ones) to assess E–R consistency and interpreting the potential causal effects with totality of evidence (including dose–response results) should be implemented to better inform dosing decisions.
- 25 September 2025
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 14 (12) , 2118-2127
Open AccessEvaluation and Mitigation of Time‐Dependent Confounding Effects in Conventional Exposure‐Response Analyses for Oncology Drugs
Conventional exposure–response (E–R) analyses, such as logistic regression and time‐to‐event analysis using summary exposure metrics, are often conducted in oncology using data from the pivotal trial(s) with a single dose level to support dosing decisions. However, these E–R analyses, affected by multiple confounding factors, may mischaracterize true E–R relationships, potentially limiting their utility in dosing decisions. This study investigates potential mischaracterization in such analyses influenced by the following time‐dependent confounding factors: exposure accumulation, dose modification patterns, and event onset time. We used a simulation‐based approach to evaluate two E–R scenarios: ER1, where event time generated with a Weibull distribution is not affected by drug exposure, and ER2, where the response is driven by drug exposure via a joint PK‐tumor size model. Our analyses indicate that when using time‐dependent exposure metrics (e.g., average concentration till event/censoring), exposure accumulation tends to induce an inverse E–R trend, while dose modifications (interruptions/reductions) likely induce a positive E–R trend. Simulations suggest that employing static exposure metrics (e.g., first‐cycle or steady‐state) minimizes these biases. Additionally, adopting an E max model aligned with the underground truth in ER2 in the E–R analyses could reduce bias. When significant dose modifications are present, including relevant data from a dose‐range study and employing modified methods for time‐dependent exposure derivation may help mitigate bias. Overall, using multiple exposure metrics (including static ones) to assess E–R consistency and interpreting the potential causal effects with totality of evidence (including dose–response results) should be implemented to better inform dosing decisions.
- 25 August 2025
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 65 (12) , 1637-1649
Application of Lactation Physiologically Based Pharmacokinetic Modeling to Predict Milk Exposure of Passively Diffused Drugs
Physiologically based pharmacokinetic (PBPK) models have gained interest as a tool for predicting drug transfer to human milk and assessing the exposure levels in infants. Our group previously developed an integrated lactation PBPK model framework to understand the transfer of drugs into milk and the resulting exposure in infants. As a part of the framework, the current paper focuses on performance of lactation PBPK models to predict maternal plasma and milk concentrations for drugs that are not substrates of P‐glycoprotein (P‐gp) or breast cancer resistance protein (BCRP) transporters—atenolol, escitalopram, and alprazolam. PBPK models for healthy adult subjects were developed for atenolol and escitalopram in Simcyp v23 and verified against clinical data. For alprazolam, the Simcyp library model was used. The built‐in lactation compartment in Simcyp was utilized for the three drugs. Atenolol and escitalopram adult healthy PBPK models showed agreement of plasma concentration–time profiles with respective clinical data. The lactation PBPK models predicted milk concentration profiles with reasonable agreement for all three drugs as well. The predicted milk concentration–time profile, milk pharmacokinetic parameters and milk‐to‐plasma (M/P) ratio of atenolol, alprazolam, and escitalopram were within 2‐fold of the reported values, suggesting agreement between simulation and clinical data. The current work shows the potential of lactation PBPK models to predict drug exposure in human milk for drugs that are not P‐gp or BCRP substrates. The approach will be further evaluated for drugs that are substrates for these active transporters known to be present in mammary tissues.
- 25 August 2025
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 65 (12) , 1637-1649
Application of Lactation Physiologically Based Pharmacokinetic Modeling to Predict Milk Exposure of Passively Diffused Drugs
Physiologically based pharmacokinetic (PBPK) models have gained interest as a tool for predicting drug transfer to human milk and assessing the exposure levels in infants. Our group previously developed an integrated lactation PBPK model framework to understand the transfer of drugs into milk and the resulting exposure in infants. As a part of the framework, the current paper focuses on performance of lactation PBPK models to predict maternal plasma and milk concentrations for drugs that are not substrates of P‐glycoprotein (P‐gp) or breast cancer resistance protein (BCRP) transporters—atenolol, escitalopram, and alprazolam. PBPK models for healthy adult subjects were developed for atenolol and escitalopram in Simcyp v23 and verified against clinical data. For alprazolam, the Simcyp library model was used. The built‐in lactation compartment in Simcyp was utilized for the three drugs. Atenolol and escitalopram adult healthy PBPK models showed agreement of plasma concentration–time profiles with respective clinical data. The lactation PBPK models predicted milk concentration profiles with reasonable agreement for all three drugs as well. The predicted milk concentration–time profile, milk pharmacokinetic parameters and milk‐to‐plasma (M/P) ratio of atenolol, alprazolam, and escitalopram were within 2‐fold of the reported values, suggesting agreement between simulation and clinical data. The current work shows the potential of lactation PBPK models to predict drug exposure in human milk for drugs that are not P‐gp or BCRP substrates. The approach will be further evaluated for drugs that are substrates for these active transporters known to be present in mammary tissues.
- 16 April 2025
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 65 (9) , 1176-1180
Clinical Pharmacology Guidances Advancing Drug Development and Regulatory Assessment: Role and Opportunities
- 16 April 2025
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 65 (9) , 1176-1180
Clinical Pharmacology Guidances Advancing Drug Development and Regulatory Assessment: Role and Opportunities